EZH2 and neoplasm: Specifically, recent studies have shown that EZH2 inhibition can increase tumor expression of the disialoganglioside GD2 and enhance efficacy of anti-GD2 therapies (Kailayangiri et al., 2019; Mabe et al., 2022).